1. Lazaridis, K. N. & LaRusso, N. F. Primary sclerosing cholangitis. N Engl J Med 375, 1161–1170 (2016).
2. Iwasawa, K. et al. Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis.Gut 66, 1344–1346 (2017).
3. Feldstein, A. E. et al. Primary sclerosing cholangitis in children: A long-term follow-up study. Hepatology 38, 210–217 (2003).
4. Deneau, M. R. et al. The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration.Hepatology, https://doi.org/10.1002/hep.29204 (2017).
5. Lunder, A. K. et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology 151, 660–669 e664 (2016).
6. Alexopoulou, E. et al. Investigative MRI cholangiopancreatography for primary sclerosing cholangitis-type lesions in children with IBD. J Pediatr Gastroenterol Nutr 55, 308–313 (2012).
7. Chapman, R. et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 51, 660–678 (2010).
8. Ferrara, C., Valeri, G., Salvolini, L. & Giovagnoni, A. Magnetic resonance cholangiopancreatography in primary sclerosing cholangitis in children. Pediatr Radiol 32, 413–417 (2002).
9. Rossi, G. et al. Diagnosis of sclerosing cholangitis in children: Blinded, comparative study of magnetic resonance versus endoscopic cholangiography. Clin Res Hepatol Gastroenterol 37, 596–601 (2013).
10. Davies, Y. K. et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: An immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 47, 61–67 (2008).
11. Farkkila, M. et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trial. Hepatology 40, 1379–1386 (2004).
12. Silveira, M. G. et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: Results of a pilot study. Am J Gastroenterol 104, 83–88 (2009).
13. Tabibian, J. H. et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis — A pilot study. Aliment Pharmacol Ther 37, 604–612 (2013).
14. Rahimpour, S. et al. A Triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: A pilot study. J Gastrointestin Liver Dis 25, 457–464 (2016).
15. Rossen, N. G. et al. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis 9, 342–348 (2015).
16. Kevans, D. et al. Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis. J Crohns Colitis 10, 330–337 (2016).
17. Torres, J. et al. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther 43, 790–801 (2016).
18. Quraishi, M. N. et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. Gut 66, 386–388 (2017).
19. Kummen, M. et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 66, 611–619 (2017).
20. Sabino, J. et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 65, 1681–1689 (2016).
21. Ruhlemann, M. C. et al. Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. Gut 66, 753–754 (2017).
22. Torres, J. et al. The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. United European Gastroenterol J, 205064061770895, https://doi.org/10.1177/2050640617708953 (2017).
23. Bajer, L. et al. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol 23, 4548–4558 (2017).
24. Clemente, J. C., Ursell, L. K., Parfrey, L. W. & Knight, R. The impact of the gut microbiota on human health: An integrative view. Cell 148, 1258–1270 (2012).
25. Bajaj, J. S. et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology 62, 1260–1271 (2015).
26. Said, H. S. et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Res 21, 15–25 (2014).
27. Atarashi, K. et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science 358, 359–365 (2017).
28. Farrell, J. J. et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 61, 582–588 (2012).
29. Torres, P. J. et al. Characterization of the salivary microbiome in patients with pancreatic cancer. PeerJ 3, e1373, https://doi. org/10.7717/peerj.1373 (2015).
30. Yan, X. et al. Discovery and validation of potential bacterial biomarkers for lung cancer. Am J Cancer Res 5, 3111–3122 (2015).
31. Flemer, B. et al. The oral microbiota in colorectal cancer is distinctive and predictive. Gut, https://doi.org/10.1136/ gutjnl-2017-314814 (2017).
32. Piccolo, M. et al. Salivary microbiota associated with immunoglobulin A nephropathy. Microb Ecol 70, 557–565 (2015).
33. Francavilla, R. et al. Salivary microbiota and metabolome associated with celiac disease. Appl Environ Microbiol. 80, 3416–3425 (2014).
34. Coit, P. et al. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behcet’s disease. Clin Immunol 169, 28–35 (2016).
35. Zhang, X. et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med21, 895–905 (2015).
36. Ding, T. & Schloss, P. D. Dynamics and associations of microbial community types across the human body. Nature 509, 357–360 (2014).
37. Levine, A. et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 58, 795–806 (2014).
38. Kim, S. W. et al. Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high-throughput pyrosequencing. DNA Res 20, 241–253 (2013).
39. Singleton, D. R., Furlong, M. A., Rathbun, S. L. & Whitman, W. B. Quantitative comparisons of 16S rRNA gene sequence libraries from environmental samples. Appl Environ Microbiol 67, 4374–4376 (2001).
40. Good, I. J. The population frequencies of species and the estimation of population parameters. Biometrika 40, 237–264 (1953).
41. Calle, M. L., Urrea, V., Boulesteix, A. L. & Malats, N. AUC-RF: A new strategy for genomic profiling with random forest. Hum Hered72, 121–132 (2011).
42. Lu, H. et al. Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma. Sci Rep 6, 33142, https:// doi.org/10.1038/srep33142 (2016).
43. Razumilava, N., Gores, G. J. & Lindor, K. D. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 54, 1842–1852 (2011).
44. Takayasu, L. et al. Circadian oscillations of microbial and functional composition in the human salivary microbiome. DNA Res, https://doi.org/10.1093/dnares/dsx001 (2017).
45. Takeshita, T. et al. Bacterial diversity in saliva and oral health-related conditions: The Hisayama Study. Sci Rep 6, 22164, https://doi. org/10.1038/srep22164 (2016).
46. Tada, S., Ebinuma, H., Saito, H. & Hibi, T. Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis. J Gastroenterol 41, 388–389 (2006).
47. Kozaiwa, K. et al. Three paediatric cases of primary sclerosing cholangitis treated with ursodeoxycholic acid and sulphasalazine. J Gastroenterol Hepatol 13, 825–829 (1998).
48. Zaura, E. et al. Same exposure but two radically different responses to antibiotics: Resilience of the salivary microbiome versus long- term microbial shifts in feces. MBio 6, e01693–01615, https://doi.org/10.1128/mBio.01693-15 (2015).
49. Morita, H. et al. An improved DNA isolation method for metagenomic analysis of the microbial flora of the human intestine.Microbes Environ 22, 214–222 (2007).
50. Lozupone, C., Lladser, M. E., Knights, D., Stombaugh, J. & Knight, R. UniFrac: An effective distance metric for microbial community comparison. ISME J 5, 169–172 (2011).